These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23571389)

  • 41. [Innovations in the treatment of type 2 diabetes mellitus: use of incretins].
    Dedov II; Shestakova MV; Sukhareva OIu
    Ter Arkh; 2010; 82(10):5-10. PubMed ID: 21341455
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
    Olansky L
    Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
    [No Abstract]   [Full Text] [Related]  

  • 44. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
    Camafort-Babkowski M
    Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparing incretin-based therapies. Evaluating GLP-1 agonists and DPP-4 inhibitors for type 2 diabetes mellitus.
    Urquhart BS
    Adv NPs PAs; 2010 Oct; 1(2):38-44. PubMed ID: 21299149
    [No Abstract]   [Full Text] [Related]  

  • 47. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.
    Liu J; Li L; Deng K; Xu C; Busse JW; Vandvik PO; Li S; Guyatt GH; Sun X
    BMJ; 2017 Jun; 357():j2499. PubMed ID: 28596247
    [No Abstract]   [Full Text] [Related]  

  • 48. Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?
    Campbell IW
    Int J Clin Pract; 2010 May; 64(6):791-801. PubMed ID: 20518953
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Glucagon-like peptide-1 receptor agonists].
    Kurose T; Seino Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():689-92. PubMed ID: 22768599
    [No Abstract]   [Full Text] [Related]  

  • 50. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
    Ryan GJ; Hardy Y
    J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes.
    Verge D; López X
    Curr Diabetes Rev; 2010 Jul; 6(4):191-200. PubMed ID: 20380625
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The future of incretin-based therapy: novel avenues--novel targets.
    Ahrén B
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():158-66. PubMed ID: 21824270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incretin hormone mimetics and analogues in diabetes therapeutics.
    Green BD; Flatt PR
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):497-516. PubMed ID: 18054732
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Helping patients make sense of the risks of taking GLP-1 agonists.
    Montori VM
    BMJ; 2013 Jun; 346():f3692. PubMed ID: 23751906
    [No Abstract]   [Full Text] [Related]  

  • 56. Incretin Physiology and Pharmacology in the Intensive Care Unit.
    Plummer MP; Hermanides J; Deane AM
    Crit Care Clin; 2019 Apr; 35(2):341-355. PubMed ID: 30784614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. GLP-1 receptor agonists: effects on cardiovascular risk reduction.
    Lorber D
    Cardiovasc Ther; 2013 Aug; 31(4):238-49. PubMed ID: 23865382
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treating diabetes with incretin hormones - clinical experience.
    Handelsman Y
    Pediatr Endocrinol Rev; 2008 Jun; 5(4):897-903. PubMed ID: 18552752
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incretin based therapies: bone protective effects.
    Chakhtoura M; Azar ST
    Endocr Metab Immune Disord Drug Targets; 2013 Dec; 13(4):289-94. PubMed ID: 24138054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.